Active Recombinant Human EBI3&IL12A, MIgG2a Fc-tagged
Cat.No. : | EBI3&IL12A-122H |
Product Overview : | The human IL-35 complex composed of the Ebi3 subunit(NP_005746.2) (Arg21-Lys229) and the IL-12a(p35) subunit (NP_000873.2)(Arg57-Ser253) is fused through a polypeptide linker to the Fc portion of mouse IgG2awas expressed in CHO cell |
- Specification
- Gene Information
- Related Products
Description : | The gene EBI3 was identified by its induced expression in B lymphocytes in response Epstein-Barr virus infection. It encodes a secreted glycoprotein belonging to the hematopoietin receptor family, and heterodimerizes with a 28 kDa protein to form interleukin 27 (IL-27). IL-27 regulates T cell and inflammatory responses, in part by activating the Jak/STAT pathway of CD4+ T cells, while the other gene IL12A encodes a subunit of a cytokine that acts on T and natural killer cells, and has a broad array of biological activities. The cytokine is a disulfide-linked heterodimer composed of the 35-kD subunit encoded by this gene, and a 40-kD subunit that is a member of the cytokine receptor family. This cytokine is required for the T-cell-independent induction of interferon (IFN)-gamma, and is important for the differentiation of both Th1 and Th2 cells. The responses of lymphocytes to this cytokine are mediated by the activator of transcription protein STAT4. Nitric oxide synthase 2A (NOS2A/NOS2) is found to be required for the signaling process of this cytokine in innate immunity. |
Source : | CHO cells |
Species : | Human |
Tag : | MIgG2a Fc-tagged |
Form : | Lyophilized from 0.2μm-filtered solution in PBS. |
Bio-activity : | Bioactivity was measured in a cell proliferation assay using anti-CD3 activated human peripheral mononuclear cells. |
Molecular Mass : | 75 KDa (monomer) |
AA Sequence : | The human IL-35 complex composed of the Ebi3 subunit(NP_005746.2) (Arg21-Lys229) and the IL-12a(p35) subunit (NP_000873.2)(Arg57-Ser253) is fused through a polypeptide linker to the Fc portion of mouse IgG2a. |
Endotoxin : | <0.06 eu/μg as determined by lal test.>0.06> |
Purity : | >98%, by SDS-PAGE under reducing conditions. |
Stability : | Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
Reconstitution : | Reconstitute at 100μg/ml in sterile PBS. |
Warning : | Avoid freeze/thaw cycles. |
Gene Name : | EBI3; IL12A |
Official Symbol : | IL35 |
Synonyms : | P35; CLMF; NFSK; NKSF1; IL-12A;IL27B; IL-27B; EBI3; Epstein-Barr virus induced 3 |
Gene ID : | 10148; 3592 |
mRNA Refseq : | NM_000882& NM_005755 |
Protein Refseq : | NP_005746& NP_000873 |
MIM : | 161560& 605816 |
UniProt ID : | Q14213&P29459 |
Chromosome Location : | 3q25.33&19p13.3 |
Products Types
◆ Recombinant Protein | ||
IL35-1039H | Recombinant Human IL12A & IL27B Heterotrimer Protein (Met1-Ser219 & Met1-Lys229), His-Flag-tagged | +Inquiry |
Il12a&Ebi3-110M | Active Recombinant Mouse Il12a&Ebi3, HIgG1 Fc-tagged | +Inquiry |
Il12a&Ebi3-111M | Active Recombinant Mouse Il12a&Ebi3, HIgG1 Fc-tagged | +Inquiry |
IL35-0219H | Recombinant Human IL35 protein, Fc-tagged | +Inquiry |
EBI3&IL12A-121H | Active Recombinant Human EBI3&IL12A, MIgG2a Fc-tagged | +Inquiry |
◆ Lysates | ||
IL35-2904HCL | Recombinant Human IL35 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionThe dosage of IL35 is usually determined in clinical trials and adjusted according to the specific situation of the patient.
The IL35 works by regulating the function and activity of immune cells, thereby influencing the immune response of the immune system.
Recombinant IL35 can inhibit the activity of the immune system, thereby regulating the inflammatory response and the function of immune cells.
Combination use of IL35 needs to be evaluated in clinical practice to determine possible interactions and safety.
The efficacy of IL35 is typically evaluated by biomarkers in clinical trials, degree of disease remission, and patient feedback.
IL35 shows potential to treat certain autoimmune diseases, but further research is needed to determine its effectiveness and safety.
Customer Reviews (3)
Write a reviewIL34 can maintain its biological activity and structural integrity under specific experimental conditions.
IL35 has high chemical and physical stability and is suitable for long-term storage and use.
Products undergo strict quality control to ensure the consistency and stability of each batch.
Ask a Question for All IL35 Products
Required fields are marked with *
My Review for All IL35 Products
Required fields are marked with *
Inquiry Basket